ProCE Banner Activity

Selecting and Sequencing BTK Inhibitor Therapy in Relapsed/Refractory MCL

Slideset

Download these slides from a live symposium at ASH 2023 to learn more about how to select and sequence BTK inhibitors for patients with relapsed/refractory MCL.

Released: December 06, 2023

Share

Faculty

Ann LaCasce

Ann LaCasce, MD, MMSc

Associate Professor of Medicine
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca